The presentations will highlight findings on the utility of Signatera for MRD assessment in colorectal (CRC), esophageal, gastric and anal cancers, in a total of five presentations.
On the heels of the groundbreaking CIRCULATE-Japan results just released, we are excited to share additional data further underscoring the real-world utility of Signatera in GI cancers,' said
Through our study, we've shown for the first time in a large, real-world setting that MRD testing with Signatera could be performed starting at 2 weeks, without compromising test sensitivity,' said
The full list of Signatera presentations and activities during ASCO GI is below.
Oral presentations
Presenter:
Kinetics of postoperative circulating cell-free DNA and impact on minimal residual disease detection rates in patients with resected stage I-III colorectal cancer
Presenter:
Circulating Tumor DNA (ctDNA) Provides a Rapid and Early Response Assessment in Patients with Anal Cancer Treated with Definitive Chemoradiation
This oral presentation in Anal cancer follows a separate study published recently in The Oncologist, which demonstrated Signatera's performance in over 250 patients with anal squamous cell carcinoma.
Posters and Industry Session
Presenter:
Circulating tumor DNA as a marker of recurrence risk in locoregional esophagogastric cancers with pathologic complete response
Presenter: Rutika Mehta, M.D.,
Circulating tumor DNA (ctDNA) informs clinical practice in patients with recurrent/metastatic gastroesophageal cancers
Presenter:
Feasibility and dynamics of preoperative circulating tumor DNA in gastroesophageal cancer patients receiving preoperative treatment
Presenter:
Applications of personalized ctDNA testing to optimize treatment decisions in patients with GI cancers
Additional data recently published on Anal squamous carcinoma (SCCA)
A recent study published in The Oncologist highlights Signatera's utility in anal squamous cell carcinoma (SCCA). The paper reports results from a real-world study of 251 patients (817 plasma samples) with stage I-IV SCCA who were monitored longitudinally after completion of definitive treatment. In a subset of patients with complete clinical follow-up, ctDNA-positivity at any time after definitive treatment was associated with significantly shorter disease-free survival. Among the ctDNA-negative patients, all except one remained disease free on imaging (NPV 95.7%). Additionally, analysis of whole exome sequencing data from all 251 patients found significant genomic heterogeneity, further highlighting the value of a personalized and tumor-informed approach to ctDNA testing.
About Signatera
Signatera is a custom-built circulating tumor DNA (ctDNA) test for treatment monitoring and molecular residual disease (MRD) assessment in patients previously diagnosed with cancer. The test is available for both clinical and research use, and has been granted three Breakthrough Device Designations by the FDA for multiple cancer types and indications. The Signatera test is personalized and tumor-informed, providing each individual with a customized blood test tailored to fit the unique signature of clonal mutations found in that individual's tumor. Signatera is intended to detect and quantify cancer left in the body, at levels down to a single tumor molecule in a tube of blood, to identify recurrence earlier and to help optimize treatment decisions.
About Natera
Natera is a global leader in cell-free DNA testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are validated by more than 100 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in
Forward-Looking Statements
All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in 'Risk Factors' in Natera's recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the
Contact:
Tel: 510-826-2350
(C) 2023 Electronic News Publishing, source